Celularity Inc. (NASDAQ:CELU)

RELEASE: Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law Read it here: globenewswire.com/news-release/2…

Release: Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies globenewswire.com/news-release/2…

Advancing Ocular Surface Reconstruction: Our DDHAM-3L technology, with its unique biological properties, offers a promising platform for delivering patient-specific, iPSC-derived LSCs to restore vision and improve patient outcomes. globenewswire.com/news-release/2…

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products Read the full release here: globenewswire.com/news-release/2…

An important publication form our team in Frontiers in Immunology: Senescence, NK Cells, and Cancer. Read the full release - with link to the publication - here: globenewswire.com/news-release/2…

Excited to receive FDA Tissue Reference Group recommendation letters on the newest additions to our portfolio of human placental-derived biomaterials. Full story here: globenewswire.com/news-release/2…

We are delighted to announce a strategic collaboration with BlueSphere Bio, Inc., which will bring together our core strengths in cell manufacturing, process development and BSB’s development of novel cell therapies to treat high risk leukemias. globenewswire.com/news-release/2…

Celularity Founder and CEO Dr. Robert Hariri to be a Keynote Speaker at the Longevity Med Summit this May, discussing cellular therapies for human performance and longevity. #longevity #stemcells lifespan.io/news/the-3rd-l…

A great feature in Drug Target Review's Beyond the Lab Report on the work Celularity is doing in the realm of stem cell therapies. (Found on page 6.) indd.adobe.com/view/d551a70e-…

Celularity, Inc. is proud to be a member of the MASS Coalition, a group of business leaders who together are working with the new administration to prevent amputation and other complications associated with Diabetes and Cardiovascular disease.  saveourwoundcare.org/media/

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million! Read the full release here: globenewswire.com/news-release/2…

Celularity's CEO, @DrBobHariri named as one of the Top 50 Biotech Entrepreneurs of 2024 by Great Entrepreneurs! thegreatentrepreneurs.com/the-top-50-bio… #biotech #innovation #entrepreneur

Celularity CEO Dr. Robert Hariri interviewed by @_CellandGene to discuss breakthroughs in genetic engineering & promising non-viral vectors in clinical trials. cellandgene.com/doc/inside-the…

Exciting news! We have added to our portfolio of placental-derived advanced biomedical products with the acquisition of Rebound. The full release can be read here: globenewswire.com/news-release/2…

Celularity's CEO, Dr. Robert Hariri, was interviewed on the Health Care Rounds Podcast, discussing Celularity's cutting-edge innovations, and the future of medicine. The episode is out now and linked below. youtu.be/9KmpAGyMRQM?si…

Excited about the growth we’ve been experiencing at Celularity. Expecting a 290% growth over the first half of 2023 in the first half of 2024. On track for the 510(k) submission of our Celularity Tendon Wrap in 2025. It’s an exciting time at Celularity! tinyurl.com/y7jzjdz8

A great interview from @AuthorityMgzine with Celularity's CEO Dr. Robert Hariri on what it takes to change an industry. medium.com/authority-maga…

Celularity CEO Dr. Robert Hariri cited in this interesting article on the quantity and quality of data available to the biotech industry and the role of AI in digesting and deciphering it. Link to the full article here: liebertpub.com/doi/10.1089/ge…

Amplifying our success through strategic partnerships and collaboration: In this clip from Celularity's Investor & Analyst R&D presentation, our CEO elaborates on how our internal talent allows for collaboration and partnerships with leading companies and academic institutions.

A World Class Facility for Commercial Scale Manufacturing: In this clip from Celularity's Investor & Analyst R&D day presentation, our CEO Dr. Robert Hariri describes the capabilities and opportunities of our manufacturing infrastructure. #biotech #stemcells